We also provide evidence that UDCA, an FDA approved drug that along with analogues is in clinical trials for ALS, Parkinson’s disease and Alzheimer’s disease but whose precise therapeutic target is unclear, rescues TDP43 induced damage to the VAPB-PTPIP51 interaction. This evidence concerns the gene RMDN3 and early-onset autosomal dominant Alzheimer disease.